Clinical Trial Detail

NCT ID NCT03310957
Title Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Seattle Genetics, Inc.
Indications

triple-receptor negative breast cancer

Therapies

Ladiratuzumab vedotin + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.